SCHEMBL6165957

SCHEMBL6165957

N#Cc1cccc(NC(=O)Cc2ccccc2-c2cccc(C#N)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.64
ALDH1A1 P00352 4/20 0.57
DUSP3 P51452 1/20 0.57
MAPK1 P28482 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HSD17B10 Q99714 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
ADRA2C P18825 1/20 0.53
KMT2A Q03164 4/20 0.51
ACHE P22303 1/20 0.50
BACE1 P56817 1/20 0.50
TSHR P16473 1/20 0.50
MAPT P10636 3/20 0.49
MEN1 O00255 2/20 0.49
HPGD P15428 1/20 0.48
HTT P42858 2/20 0.48
RORC P51449 1/20 0.48
GRM4 Q14833 1/20 0.47
POLB P06746 1/20 0.47
PTK2B Q14289 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6163952 0.93 LMNA (0.57) LMNAALDH1A1DUSP3MAPK1SMN1; SMN2
SCHEMBL7101534 0.91 LMNA (0.63) LMNAALDH1A1DUSP3MAPK1SMN1; SMN2
SCHEMBL7108448 0.91 LMNA (0.53) LMNAALDH1A1DUSP3MAPK1SMN1; SMN2
SCHEMBL6164911 0.81 ADRA2C (0.61) LMNAADRA2C
SCHEMBL6166508 0.80 ADRA2C (0.56) LMNAALDH1A1MAPK1ADRA2CKMT2A
SCHEMBL6167046 0.79 RORC (0.49) LMNAALDH1A1SMN1; SMN2KMT2ATSHR
SCHEMBL29767752 0.79 LMNA (1.00) LMNAALDH1A1DUSP3MAPK1SMN1; SMN2
SCHEMBL6164487 0.77 MAPT (0.62) LMNAALDH1A1SMN1; SMN2HSD17B10KMT2A
SCHEMBL8639463 0.76 CYP1A2 (0.63) LMNAALDH1A1SMN1; SMN2HSD17B10L3MBTL1
SCHEMBL6166155 0.75 ADRA2C (0.68) ALDH1A1SMN1; SMN2ADRA2CTSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1254136-A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD (KR) 2005-06-01 EP disclosed
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof LG CHEM INVESTMENT LTD. (KR) 2003-04-03 US disclosed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 EP disclosed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof F2, F12, TFPI LMNA 772/4885ALDH1A1 1388/4885DUSP3 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.